We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
Read MoreHide Full Article
Key Takeaways
NVCR submitted a PMA to the FDA for TTFields use in locally advanced pancreatic cancer treatment.
NovoCure's application is backed by PANOVA-3 trial data and may convert into a separate PMA by late 2026.
NVCR aims to strengthen its position in oncology by expanding TTFields therapy to new indications.
NovoCure Limited (NVCR - Free Report) , on Wednesday, announced its submission of a premarket approval (PMA) application to the FDA for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. The approval decision is anticipated in the second half of 2026.
It is worth mentioning that TTFields, which is NovoCure’s proprietary platform technology, are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
The PMA submission is a significant milestone for NovoCure, which is likely to strengthen its foothold in the global oncology space.
Likely Trend in NVCR Stock Following the News
Following the announcement, shares of the company lost nearly 1.3% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations. Although the latest announcement is likely to be beneficial for NVCR’s top-line growth going forward, the stock declined overall.
NovoCure currently has a market capitalization of $1.33 billion. It has a P/S ratio of 2.1, lower than the industry’s 5.8. In the last reported quarter, NVCR delivered an earnings surprise of 7.7%.
Significance of NovoCure’s Announcement
Per NovoCure, the PMA application submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for adults with unresectable, locally advanced pancreatic adenocarcinoma, compared to GnP alone.
The PMA for pancreatic cancer was submitted as a PMA Panel-Track Supplement to Optune Lua, which is currently indicated for the treatment of patients with non-small cell lung cancer. The PMA supplement is expected to be converted to a separate, original PMA for the treatment of pancreatic cancer.
Management believes that the submission of the application is a key step in NVCR’s efforts to advance TTFields therapy as a treatment option for people with pancreatic cancer.
Industry Prospects in Favor of NVCR
Per a report by Grand View Research, the global pancreatic cancer treatment market was estimated at $2.92 billion in 2024 and is anticipated to reach $5.84 billion by 2030 at a CAGR of 12.3%. Factors like the rise in lifestyle-related diseases and a growing elderly population are likely to drive the market.
Given the market potential, the latest announcement is expected to provide a significant boost to NovoCure’s business.
NovoCure’s Notable Development
In July, NovoCure announced its second-quarter 2025 results, wherein the total net revenues for the quarter increased 5.6% year over year. This increase was primarily driven by active patient growth across its major markets. Also, as of June 30, 2025, there were 4,331 total active patients on TTFields therapy globally.
NVCR’s Share Price Performance
Shares of the company have lost 33.2% in the past year compared with the industry’s 14% decline. The S&P 500 has gained 13.8% in the same time frame.
Image Source: Zacks Investment Research
NovoCure’s Zacks Rank & Key Picks
Currently, NVCR carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are LeMaitre Vascular, Inc. (LMAT - Free Report) , Encompass Health Corporation (EHC - Free Report) and Envista Holdings Corporation (NVST - Free Report) .
LeMaitre Vascular, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17%. LMAT’s earnings surpassed estimates in two of the trailing four quarters, missed once and broke even in the other, the average surprise being 3.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
LeMaitre Vascular’s shares have gained 5.2% compared with the industry’s 3.6% growth in the past year.
Encompass Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.9%. EHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14%.
Encompass Health has rallied 34.9% against the industry’s 0.2% decline in the past year.
Envista Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Envista Holdings’ shares have gained 9.4% compared with the industry’s 3.6% growth in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
Key Takeaways
NovoCure Limited (NVCR - Free Report) , on Wednesday, announced its submission of a premarket approval (PMA) application to the FDA for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. The approval decision is anticipated in the second half of 2026.
It is worth mentioning that TTFields, which is NovoCure’s proprietary platform technology, are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
The PMA submission is a significant milestone for NovoCure, which is likely to strengthen its foothold in the global oncology space.
Likely Trend in NVCR Stock Following the News
Following the announcement, shares of the company lost nearly 1.3% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations. Although the latest announcement is likely to be beneficial for NVCR’s top-line growth going forward, the stock declined overall.
NovoCure currently has a market capitalization of $1.33 billion. It has a P/S ratio of 2.1, lower than the industry’s 5.8. In the last reported quarter, NVCR delivered an earnings surprise of 7.7%.
Significance of NovoCure’s Announcement
Per NovoCure, the PMA application submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for adults with unresectable, locally advanced pancreatic adenocarcinoma, compared to GnP alone.
The PMA for pancreatic cancer was submitted as a PMA Panel-Track Supplement to Optune Lua, which is currently indicated for the treatment of patients with non-small cell lung cancer. The PMA supplement is expected to be converted to a separate, original PMA for the treatment of pancreatic cancer.
Management believes that the submission of the application is a key step in NVCR’s efforts to advance TTFields therapy as a treatment option for people with pancreatic cancer.
Industry Prospects in Favor of NVCR
Per a report by Grand View Research, the global pancreatic cancer treatment market was estimated at $2.92 billion in 2024 and is anticipated to reach $5.84 billion by 2030 at a CAGR of 12.3%. Factors like the rise in lifestyle-related diseases and a growing elderly population are likely to drive the market.
Given the market potential, the latest announcement is expected to provide a significant boost to NovoCure’s business.
NovoCure’s Notable Development
In July, NovoCure announced its second-quarter 2025 results, wherein the total net revenues for the quarter increased 5.6% year over year. This increase was primarily driven by active patient growth across its major markets. Also, as of June 30, 2025, there were 4,331 total active patients on TTFields therapy globally.
NVCR’s Share Price Performance
Shares of the company have lost 33.2% in the past year compared with the industry’s 14% decline. The S&P 500 has gained 13.8% in the same time frame.
Image Source: Zacks Investment Research
NovoCure’s Zacks Rank & Key Picks
Currently, NVCR carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are LeMaitre Vascular, Inc. (LMAT - Free Report) , Encompass Health Corporation (EHC - Free Report) and Envista Holdings Corporation (NVST - Free Report) .
LeMaitre Vascular, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17%. LMAT’s earnings surpassed estimates in two of the trailing four quarters, missed once and broke even in the other, the average surprise being 3.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
LeMaitre Vascular’s shares have gained 5.2% compared with the industry’s 3.6% growth in the past year.
Encompass Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.9%. EHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14%.
Encompass Health has rallied 34.9% against the industry’s 0.2% decline in the past year.
Envista Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Envista Holdings’ shares have gained 9.4% compared with the industry’s 3.6% growth in the past year.